Methods and compositions for preventing or treating cancer

ABSTRACT

The present disclosure is directed to methods and compositions for inhibiting a cancer cell using nucleic acid sequences encoding elephant p53 or elephant p53 amino acid sequences.

CROSS-REFERENCE TO RELATED APPLICATION(S)

This is a continuation of U.S. patent application Ser. No. 16/894,698, which is a divisional of U.S. patent application Ser. No. 15/767,099, filed on Apr. 9, 2018, now issued as U.S. Pat. No. 10,709,761 on Jul. 14, 2020, which is a U.S. national stage entry of International Patent Application No. PCT/US2016/055921, filed on Oct. 7, 2016, which claims priority to U.S. Provisional Patent Application No. 62/379,179, filed on Aug. 24, 2016, and U.S. Provisional Patent Application No. 62/239,103, filed on Oct. 8, 2015, the entire contents of each of which are fully incorporated herein by reference.

INCORPORATION-BY-REFERENCE OF MATERIAL SUBMITTED ELECTRONICALLY

This application was filed with a Sequence Listing XML in ST.26 XML format in accordance with 37 C.F.R. § 1.821. The Sequence Listing XML file submitted in the USPTO Patent Center, “026389-9173-US04.xml,” was created on Oct. 2, 2023, contains 77 sequences, has a file size of 121 Kbytes, and is incorporated by reference in its entirety into the specification.

BACKGROUND OF THE INVENTION

Multicellular organisms have intrinsic defenses to protect against the development of mutations and cancer. One such defense mechanism is the signaling pathways regulated by tumor protein p53 (encoded by the gene TP53), which is a critical suppressor of cancer. Referred to as the “guardian of the genome,” p53 is able to halt cell division when DNA damage is detected and either initiate correction of the mutation, or trigger apoptosis if the damage is irreparable (Blagosklonny. Int J Cancer, 98: 161-166(2002)). Humans contain one copy (two alleles) of TP53, and both functioning alleles are crucial to prevent cancer development. The absence of even one functional allele leads to Li-Fraumeni Syndrome (LFS), a cancer predisposition in which patients have a 90% chance of developing cancer during their lifetime (McBride et al. Nat Rev Clin Oncol; 11(5): 260-271 (2014)). Inactivation of p53 also can lead to cancer (Lane, DP. Nature; 358(6381): 15-16 (2014); Hanahan et al. Cell; 144(5): 646-674 (2011)), and in humans p53 function naturally decreases with age (Feng et al., PNAS; 104(42): 16633-16638 (2007)), leaving half of all men and a third of all women susceptible to developing cancer during their lifetime (American Cancer Society; Cancer Facts & Figures (2015)). Mutations of p53 have been identified in numerous human cancers (Hollstein et al., Science; 253(5015): 49-53 (1991)).

Researchers have naturally focused on combating cancer by utilizing the protective properties of p53. For example, retrovirus- and adenovirus-mediated TP53-gene therapies have been developed to deliver human p53 to cancer cells (Cai et al. Hum Gene Ther: 4: 617-624 (1993); Brandt et al. Am J Epidemiol; 90: 484-500 (1969)), and the accumulation of p53 can be induced by disrupting its negative regulation by mouse double minute 2 (MDM2) (Vassilev et al. Science; 3i03: 844-848 (2004)). However these therapies have primarily focused on restoring the activity of wild type p53 in humans, or eliminating cancer cells with mutant p53.

Given that each cell division can potentially introduce a new genetic mutation, it was originally suspected that in larger organisms (which naturally require a greater number of cell divisions) there would be an increase in the number of mutated cells (Tomasetti et al., Science; 347(6217): 78-81 (2015)). If all mammalian cells are equally susceptible to oncogenic mutations, then cancer risk should increase with body size (number of cells) and species lifespan (number of cell divisions). However this theory was disproved over 35 years ago, as cancer incidence across animals does not appear to increase for larger body size and lifespan (Caulin et al., Trends Ecol Evolut; 26(4): 175-182 (2011); Peto et al., Br J Cancer; 32(4): 411-426 (1975)). The cellular and molecular mechanisms of this resistance to cancer in larger animals are not clearly understood, however a recent study has shown that elephants are especially resistant to developing cancer (Abegglen et al. JAMA; 314(17): 1850-60 (2015)). It was also discovered that elephants carry extra copies of the TP53 gene. Follow up studies showed that elephant p53 (EP53) is especially effective at killing cancer cells, even when the cancer cells already contained human p53.

There remains a need for compositions and methods to more effectively restore p53 function to cancerous cells. The invention provides such compositions and methods.

BRIEF SUMMARY OF THE INVENTION

The present disclosure provides a method of inhibiting cancer which comprises contacting a cancer cell with (a) one or more nucleic acid sequences each encoding an elephant p53 protein, or (b) one or more elephant p53 proteins, whereby the cancer is inhibited.

The present disclosure also provides a composition comprising a pharmaceutically acceptable carrier and (a) one or more nucleic acid sequences each encoding an elephant p53 protein or (b) one or more elephant p53 proteins.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a plot of the log(mass×life span) of 33 different mammalian species relative to the percentage of necropsies performed on each species that exhibited tumors.

FIG. 2 is a phylogenic tree showing group A and group B TP53 retrogenes in the African elephant.

FIG. 3A is an image of an electrophoresis gel showing results of TP53-specific RT-PCR performed on PBMCs from African and Asian elephants and African elephant fibroblasts. Two bands at 201 bp and 185 bp are shown, which correlate with Group A and Group B of the elephant p53 retrogenes. FIG. 3B is a higher resolution image of the PCR results depicted in FIG. 3A.

FIG. 4A and FIG. 4B are images of western blots showing that HEK293 cells transfected with EP53 retrogenes increase the expression of the proteins in response to DNA damage induced by MG132 or doxorubicin. FIG. 4C is an image of a western blot showing that HEK293 cells transfected with EP53^(r9) are able to upregulate the protein, and increase expression of the phosphorylated protein, in response to DNA damage from ionizing radiation.

FIG. 5A is a bar graph showing the percentage of elephant peripheral blood lymphocytes compared to human peripheral blood lymphocytes undergoing late apoptosis in response to 2 Gy and 6 Gy ionizing radiation. FIG. 5B is a bar graph showing the percentage of elephant peripheral blood lymphocytes compared to human peripheral blood lymphocytes undergoing early apoptosis in response to 2 Gy and 6 Gy ionizing radiation.

FIG. 6A is a bar graph showing that lymphocytes from an African elephant exhibit greater levels of late apoptosis after exposure to doxorubicin. FIG. 6B is a bar graph showing that lymphocytes from an African elephant exhibit greater levels of early apoptosis after exposure to doxorubicin.

FIG. 7 is a scatter plot showing the percentage of peripheral blood lymphocytes undergoing late apoptosis following exposure to 2 Gy ionizing radiation, from patients with Li-Fraumeni syndrome, 10 healthy controls, and 1 African elephant.

FIG. 8 is a line graph showing that elephant fibroblasts exhibit greater caspase 3/7 cleavage than human fibroblasts following exposure to doxorubicin.

FIG. 9 is an image of a western blot showing an increase in p53 and p21 protein expression 5 hours and 24 hours after 2 Gy and 6 Gy ionizing radiation.

FIG. 10A is a bar graph showing the percentage of apoptotic cells in lymphocytes from a human and an Asian elephant, 18 hours after 2 Gy ionizing radiation treatment. FIG. is an image of a western blot showing p21 protein expression in Asian elephant lymphocytes 5 hours after 2 Gy ionizing radiation. FIG. 10C is a bar graph showing the percentage of apoptotic lymphocytes in Asian elephants, sorted by age groups, 18 hours after ionizing radiation treatment.

FIG. 11A is a line graph showing an increase is caspase activity in NIH 3T3 cells transfected with EP53^(r5) following treatment with doxorubicin. FIG. 11B is a line graph showing an increase is caspase activity in NIH 3T3 cells transfected with EP53^(r9) following treatment with doxorubicin.

FIG. 12A is a line graph showing an increase in caspase activity in U-2OS cells transfected with EP53^(r6) following treatment with doxorubicin. FIG. 12B is a line graph showing an increase in caspase activity in U-2OS cells induced with EP53^(anc) following treatment with doxorubicin. FIG. 12C is an image of a western blot showing that U-2OS cells induced with EP53^(anc) and treated with doxorubicin to induce DNA damage exhibit an increase in p53 target genes, p21 and MDM2.

FIG. 13 is a western blot showing that U-2OS cells transfected with GFP-labeled EP53^(r9) exhibit an increase in phosphorylated-EP53^(r9), with a concomitant decrease in phosphorylated-human P53.

FIG. 14A is a dot plot showing that HCT 116 cells transfected with EP53^(r9) exhibit an increase in caspase activity following treatment with doxorubicin. FIG. 14B is a western blot showing that HCT 116 cells transfected with EP53^(r9) exhibit an increase in EP53^(r9) expression that correlates with increasing doses of doxycycline.

DETAILED DESCRIPTION OF THE INVENTION

The present disclosure is predicated, at least in part, on the discovery that African elephants are more resistant to cancer than humans. Cancer mortality occurs in about 11% to 25% of humans, while cancer occurs in about 3% to 6% of elephants. This increased resistance to cancer may partially be explained by the increase in genetic copies of the TP53 gene in elephants, which encodes the p53 protein. While humans only have one copy of TP53 (two alleles), elephants have at least 20 copies (40 alleles) of the elephant p53 (EP53) gene. In cell culture studies, it was found that elephant lymphocytes were more likely to execute apoptosis in response to DNA damage from ionizing radiation exposure, suggesting a lower threshold for DNA damage before elephant p53-mediated apoptosis is triggered. Elephant p53 appears to be more effective than human p53 at detecting DNA damage and removing mutated cells from an organism. The use of elephant p53 has not previously been explored as a mechanism for targeting human cancers.

Elephant p53 Sequences

The present disclosure provides a method of inhibiting cancer, which comprises contacting a cancer cell with one or more nucleic acid sequences each encoding an elephant p53 protein, or one or more elephant p53 proteins.

Nucleic acids can be single stranded or double stranded, or can contain portions of both double stranded and single stranded sequences. The nucleic acid can be DNA, and contain deoxyribonucleotides, or RNA, and contain ribonucleotides. Nucleic acids can be obtained by chemical synthesis methods or by recombinant methods. A particular nucleic acid sequence can encompass conservatively modified variants thereof (e.g., codon substitutions), alleles, orthologs, single nucleotide polymorphisms (SNPs), and complementary sequences as well as the sequence explicitly indicated.

A cancer cell may be contacted with any suitable nucleic acid sequence encoding an elephant p53 protein in any suitable combination. For example, in some embodiments, the cancer cell may be contacted with one nucleic acid sequence encoding an elephant p53 protein. In other embodiments, the cancer cell is contacted with multiple nucleic acid sequences, each encoding an elephant p53 protein. As elephants comprise at least 20 copies of the TP53 gene, the cancer cell may be contacted with 2 to 25 nucleic acid sequences (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleic acid sequences) each encoding an elephant p53 protein. In one embodiment, the one or more nucleic acid sequences encoding an elephant p53 protein is a retrogene. As used herein, the term “retrogene” refers to an RNA transcribed from a DNA gene copied back into the genome by reverse transcription. A retrogene may lack introns. The cancer cell may be contacted with multiple nucleic acid sequences each of which comprise the same retrogene, multiple different retrogenes, or combinations thereof. In addition or alternatively, the nucleic acid sequence encoding an elephant p53 protein may be an ancestral gene. As used herein, the term “ancestral gene” refers to a common gene from which a family of genes descends. An ancestral gene may be derived from ancestral gene resurrection or ancestral gene restoration, wherein the ancestral protein is inferred by means of phylogenetic methods, and a DNA molecule coding for that protein is synthesized (Chang et al., Integr Comp Biol; 43(4): 500-507 (2003)). The cancer cell may be contacted with multiple nucleic acid sequences each of which comprise the same ancestral gene, multiple different ancestral genes, or combinations thereof. In other embodiments, the cancer cell may be contacted with a combination of one or more p53-encoding retrogenes and one or more p53-encoding ancestral genes.

Examples of nucleic acid sequences of retrogenes encoding elephant p53 proteins include, but are not limited to, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 22, SEQ ID NO: 24, SEQ ID NO: 26, SEQ ID NO: 28, SEQ ID NO: 30, SEQ ID NO: 32, SEQ ID NO: 34, SEQ ID NO: 36, SEQ ID NO: 38, SEQ ID NO: 40, SEQ ID NO: 42, SEQ ID NO: 44, SEQ ID NO: 46, SEQ ID NO: 48, SEQ ID NO: 50, SEQ ID NO: 52, SEQ ID NO: 54, SEQ ID NO: 56, SEQ ID NO: 58, SEQ ID NO: 60, SEQ ID NO: 62, SEQ ID NO: 64, SEQ ID NO: 66, SEQ ID NO: 68, SEQ ID NO: 70, SEQ ID NO: 72, SEQ ID NO: 74, and SEQ ID NO: 76. An example of a nucleic acid sequence of an ancestral gene encoding an elephant p53 protein includes, but is not limited to, SEQ ID NO: 2.

For delivery to cells (e.g., cancer cells), the one or more nucleic acid sequences may be incorporated into a gene transfer vector. A “gene transfer vector” or “vector” is any molecule or composition that has the ability to carry genetic materials (e.g., a nucleic acid sequence), into a suitable host cell where the synthesis of the encoded protein takes place. Suitable vectors include, but are not limited to, plasmids, viral vectors, liposomes, lipids, polymers, inorganic nanoparticles, or chimeric vectors comprising any combination of the foregoing (e.g., a plasmid-lipid complex or a plasmid-polymer complex). Suitable viral vectors include, for example, retroviral vectors, herpes simplex virus (HSV)-based vectors, parvovirus-based vectors, sendai virus (SeV)-based vectors, adeno-associated virus (AAV)-based vectors, AAV-adenoviral chimeric vectors, and adenovirus-based vectors, and can be prepared using standard recombinant DNA techniques described in, for example, Sambrook et al., Molecular Cloning, a Laboratory Manual, 4^(th) edition, Cold Spring Harbor Press, Cold Spring Harbor, N.Y. (2012), and Ausubel et al., Current Protocols in Molecular Biology, Greene Publishing Associates and John Wiley & Sons, New York, N.Y. (2016). Suitable polymers, lipids, and inorganic nanoparticles are described in, for example, Peer et al., Nature Nanotechnology, 2:751-760 (2007), and Boussif et al., Proceedings of the National Academy of Sciences of the United States of America, 92: 7297-7301 (1995)).

In other embodiments, the cancer cell may be contacted with one or more elephant p53 proteins. A cancer cell may be contacted with any suitable elephant p53 protein in any suitable combination. As discussed above, because elephants comprise at least 20 copies of the TP53 gene, the cancer cell may be contacted with 2 to 25 p53 proteins (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 proteins). The one or more elephant p53 proteins may be encoded by one or more retrogenes, such as those described herein. For example, the cancer cell may be contacted with multiple proteins, each of which is encoded by the same retrogene, multiple different retrogenes, or combinations thereof. In addition or alternatively, the one or more elephant p53 proteins may be encoded by an ancestral gene, such as those described herein. The cancer cell may be contacted with multiple p53 proteins, each of which is encoded by the same ancestral gene, multiple different ancestral genes, or combinations thereof. In other embodiments, the cancer cell may be contacted with a combination of one or more retrogene-encoded p53 proteins and one or more ancestral gene-encoded p53 proteins.

Examples of retrogene-encoded elephant p53 amino acid sequences, but are not limited to, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 21, SEQ ID NO: 23, SEQ ID NO: 25, SEQ ID NO: 27, SEQ ID NO: 29, SEQ ID NO: 31, SEQ ID NO: 33, SEQ ID NO: 35, SEQ ID NO: 37, SEQ ID NO: 39, SEQ ID NO: 41, SEQ ID NO: 43, SEQ ID NO: 45, SEQ ID NO: 47, SEQ ID NO: 49, SEQ ID NO: 51, SEQ ID NO: 53, SEQ ID NO: 55, SEQ ID NO: 57, SEQ ID NO: 59, SEQ ID NO: 61, SEQ ID NO: 63, SEQ ID NO: 65, SEQ ID NO: 67, SEQ ID NO: 69, SEQ ID NO: 71, SEQ ID NO: 73, SEQ ID NO: 75, and SEQ ID NO: 77. An example of an ancestral gene-encoded elephant p53 amino acid sequence includes, but is not limited to SEQ ID NO: 3.

Compositions

In certain embodiments, the one or more elephant TP53 nucleic acid sequences encoding the one or more elephant p53 proteins are in the form of a composition. Thus, the present disclosure also provides a composition comprising a pharmaceutically acceptable carrier and (a) one or more nucleic acid sequences each encoding an elephant p53 protein or (b) one or more elephant p53 proteins. Any suitable pharmaceutically-acceptable carrier may be used in the context of the present disclosure, and such carriers are well known in the art. The choice of carrier will be determined, in part, by the particular site to which the composition is to be administered and the particular method used to administer the composition. Exemplary formulations for the composition include, but are not limited to, oral, injectable, and aerosol formulations.

Formulations suitable for oral administration may comprise (a) liquid solutions, such as an effective amount of the one or more nucleic acid sequences or proteins dissolved in diluents, such as water, saline, or a beverage, (b) capsules, sachets, or tablets, each containing a predetermined amount of the one or more nucleic acid sequences or proteins, as solids or granules, (c) suspensions in an appropriate liquid, and (d) suitable emulsions. Tablet forms can include one or more of lactose, mannitol, corn starch, potato starch, microcrystalline cellulose, acacia, gelatin, colloidal silicon dioxide, croscarmellose sodium, talc, magnesium stearate, stearic acid, and other excipients, colorants, diluents, buffering agents, moistening agents, preservatives, flavoring agents, and pharmacologically compatible excipients. Lozenge forms can comprise the one or more nucleic acid sequences or proteins in a flavor, usually sucrose and acacia or tragacanth, as well as pastilles comprising the active ingredient in an inert base, such as gelatin and glycerin, or sucrose and acacia, emulsions, gels, and the like containing, in addition to the one or more nucleic acid sequences or proteins, such excipients as are known in the art.

Formulations suitable for parenteral administration include aqueous and non-aqueous, isotonic sterile injection solutions, which can contain anti-oxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient, and aqueous and non-aqueous sterile suspensions that can include suspending agents, solubilizers, thickening agents, stabilizers, and preservatives. The formulations can be presented in unit-dose or multi-dose sealed containers, such as ampules and vials, and can be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid excipient, for example, water, for injections, immediately prior to use. Extemporaneous injection solutions and suspensions can be prepared from sterile powders, granules, and tablets of the kind previously described.

Formulations suitable for aerosol administration comprising the one or more nucleic acid sequences or proteins, alone or in combination with other suitable components, which can be made into aerosol formulations to be administered via inhalation. These aerosol formulations can be placed into pressurized acceptable propellants, such as dichlorodifluoromethane, propane, nitrogen, and the like. They also can be formulated as pharmaceuticals for non-pressured preparations, such as in a nebulizer or an atomizer.

Formulations suitable for topical administration may include creams, lotions, gels, ointments, or the like. Other suitable formulations are possible, for example, suppositories can be prepared by use of a variety of bases such as emulsifying bases or water-soluble bases. Formulations suitable for vaginal administration can be presented as pessaries, tampons, creams, gels, pastes, foams, or spray formulas containing, in addition to the one or more nucleic acid sequences or proteins, such carriers as are known in the art to be appropriate.

In an embodiment, suitable formulations of the composition may comprise a phase transition temperature that is equal to or lower than the thermal stability of the protein. For example, a protein with a thermal stability of 25° C. may be formulated with a phospholipid comprising a melting temperature of 23° C. (e.g., 1,2-Dimyristoyl-sn-glycero-3-phosphocholine (DMPC)). Suitable phospholipids are well known in the art.

In one aspect of the above method, the composition comprises a liposome. The term “liposome” as used herein refers to an artificially prepared vesicle composed of a lipid bilayer. The term “lipid bilayer” as used herein refers to a membrane made of two layers of lipid molecules. The lipid bilayer may have a similar thickness to that of a naturally existing bilayer, such as a cell membrane, a nuclear membrane, and a virus envelope. For example, the lipid bilayer may have a thickness of about 10 nm or less, for example, in a range of about 1 nm to about 9 nm, about 2 nm to about 8 nm, about 2 nm to about 6 nm, about 2 nm to about 4 nm, or about 2.5 nm to about 3.5 nm. The lipid bilayer is a barrier that retains nucleic acids, proteins, ions, and other molecules while also preventing them from diffusing into undesirable areas.

The “lipid molecules” forming the lipid bilayer may comprise a molecule including a hydrophilic head and a hydrophobic tail. The lipid molecule may comprise from about 14 to about 50 carbon atoms. Examples of the lipid molecules which may form a lipid bilayer include phospholipids, lipids conjugated to polyethylene glycol (PEG), cholesterol, or any combination thereof. A liposome may be classified as a unilamellar vesicle or a multilamellar vesicle. A unilamellar vesicle, as defined herein, is a single bilayer of an amphiphilic lipid or a mixture of such lipids, containing aqueous solution inside the chamber. A multilamellar vesicle consists of many concentric amphiphilic lipid bilayers.

In another aspect of the above method, the liposome may be a micelle, a bicelle, or a lipid nanodisc. As used herein, “micelle” refers to an aggregate of surfactant molecules comprising a hydrophobic interior. In some embodiments, the micelle may be comprised within the hydrophilic interior space of a liposome. A “bicelle” is a disc-shaped micelle. A micelle or a bicelle may comprise a hydrophobic nucleic acid, protein, ion, or other molecule. The term “nanodisc,” as used herein, refers to at least one phospholipid bilayer, wherein the hydrophobic edge is stabilized by at least one amphipathic protein.

In some embodiments, the one or more nucleic acid sequences or one or more elephant p53 amino acid sequences are encapsulated within a liposome.

In another embodiment, the one or more nucleic acid sequences or one or more elephant p53 proteins may be encapsulated within a nanoparticle. A “nanoparticie,” as defined herein, is a three-dimensional particle having at least one dimension that is less than 100 nm. In the context of the present disclosure, a nanoparticle may comprise a hydrophobic core and a hydrophilic layer surrounding the core. A nanoparticle may also comprise an external surface decorated with one or more moieties. As used herein, a “moiety” is a part or functional group of a molecule. The one or more moieties may be embedded in the nanoparticle core, contained within the core, attached to a molecule that forms at least a portion of the core, attached to a molecule attached to the core, or directly attached to the core. A moiety may be chosen so as to reduce the interaction of the nanoparticle with the reticuloendothelial system. Such moieties include, for example, polyethylene glycol (PEG).

In an embodiment, the one or more moieties may comprise a targeting moiety. As used herein, a “targeting moiety” directs a nanoparticle to a specific cell type, e.g., a cancer cell. The targeting moieties preferably extend outwardly from the core so that they are available for interaction with cellular components or so that they affect the surface properties of the nanoparticle. In an embodiment, the targeting moieties may be tethered to the core or components that interact with the core. The targeting moiety may comprise a small molecule carrier, such as, a cholesterol, a sugar, or insulin, to facilitate metabolic uptake of the nanoparticle. The targeting moiety may additionally comprise an antibody or a ligand that is specific for a molecule, e.g., a receptor, on the outside of the targeted cell. The one or more targeting moieties may target the nanoparticle to a specific cellular organelle, such that the nanoparticle accumulates in a specific cellular organelle, relative to other organelles or cytoplasm, at a greater concentration than a substantially similar non-targeted nanoparticle. A substantially similar non-targeted nanoparticle includes the same components in substantially the same relative concentration (e.g., within about 5%) as the targeted nanoparticle, but lacks a targeting moiety. Cellular organelles that may be targeted by the nanoparticle include, for example, the cell membrane, nucleus, nucleolus, mitochondria, golgi apparatus, golgi vesicle, rough endoplasmic reticulum, smooth endoplasmic reticulum, lysosome, peroxisome, cytoplasm, cytosol, vacuole, and secretory vesicles.

In another embodiment, the targeting moiety, e.g., a targeting peptide, cholesterol, sugar, or polyethylene glycol, may be conjugated to a variant of an elephant p53 protein to facilitate targeting a specific cell type, and/or to increase the half-life of the protein.

The nanoparticle may also comprise one or more therapeutic agents (e.g., the elephant TP53-encoding nucleic acids or p53 proteins described herein). In an embodiment, the therapeutic agent may comprise a short peptide segment of an elephant p53 protein, e.g. a peptide 13-mer in length. The therapeutic agent may be released into a specific cell type following cellular uptake of the nanoparticle, e.g., fusion of the nanoparticle with a specific cell type. In another embodiment, the therapeutic agent may be released outside of a specific cell type, and be taken up by a cellular mechanism, such as, macropinocytosis. The therapeutic agents may be contained within the nanoparticle core and released from the core at a desired rate. In some embodiments, the core may be biodegradable, releasing the one or more therapeutic agents as the core is degraded or eroded.

The composition may further comprise one or more additional agents or additives that inhibit cancer or enhance the activity of the elephant p53 nucleic acids and proteins described herein. The agent may optionally improve the efficacy of the therapeutic agent, and/or prevent inactivation, denaturation, or degradation of the therapeutic agent. For example, the composition may further comprise a small molecule chemotherapeutic, a monoclonal antibody, or an imaging agent (e.g., contrast agent, a sugar, an iron complex, or gadolinium (Gd)).

The above-described composition, one or more elephant p53-encoding nucleic acid sequences, or one or more elephant p53 proteins can be provided in a kit, i.e., a packaged combination of reagents in predetermined amounts with instructions for performing a diagnostic assay or therapeutic method. The kit may include additives, such as stabilizers, buffers, and the like, as well as instructions for use of the kit. The relative amounts of the various reagents can be varied to provide for concentrations in solution of the reagents which substantially optimize the sensitivity of the assay.

Method of Inhibiting Cancer

The present disclosure provides a method of inhibiting cancer using the one or more nucleic acid sequences each encoding an elephant p53 protein described herein, the one or more elephant p53 proteins described herein, or compositions comprising the one or more elephant nucleic acid sequences proteins described herein. The term “inhibiting cancer,” as used herein, refers to preventing, suppressing, blocking, or slowing the growth, proliferation and/or metastasis of one or more cancer cells. In some embodiments, for example, the method described herein may promote inhibition of cancer cell proliferation, inhibition of cancer cell vascularization, eradication of cancer cells, and/or a reduction in the size of at least one cancerous tumor, such that a human is treated for cancer.

The method described herein may be used to inhibit the growth, proliferation, and/or metastasis of any cancer cell type known in the art, such as, for example, bladder cancer, bone cancer, brain cancer, breast cancer, cervical cancer, colon cancer, esophageal cancer, gall bladder cancer, head and neck cancer (e.g., cancer of the oral cavity, pharynx, larynx, salivary gland, and paranasal sinuses and nasal cavity), leukemia, liver cancer, lung cancer, lymphoma, melanoma, ovarian cancer, pancreatic cancer, prostate cancer, rectal cancer, renal cell carcinoma, stomach (gastric) cancer, small intestine cancer, and thyroid cancer. The cancer cell may originate from a subject as defined herein, which desirably is a mammal, and preferably is a human (e.g., a human comprising a cancer). The cancer cell may also originate from non-human animals, for example, all mammalian and non-mammalian vertebrates (such as, but not limited to, non-human primates, sheep, dogs, cats, dogs, cows, pigs, horses, rodents, poultry, amphibians, and reptiles).

In some embodiments, the cancer cell may be a population of cancer cells, such as, for example, a primary cancer or tumor, a metastatic cancer or tumor, or a cancer tumor regrowth. In one embodiment, the cancer cell or population of cancer cells comprises a defective (e.g., mutant) TP53 gene or protein, such as a TP53 gene comprising a deletion, point mutation, insertion, substitution, or genetic rearrangement of a TP53 gene which results in altered TP53 expression (e.g., over- or under-expression), expression of a p53 protein with abnormal function, or abrogation of p53 protein expression entirely. The defective gene or deleted gene may be present in one allele (heterozygous altered), or two alleles (homozygous altered). The cancer cell or population of cancer cells may comprise a normal TP53 gene or protein, with other genomic alterations throughout the cancer cell genome.

In accordance with the methods described herein, the cancer cell may be ex vivo, in vivo, or in vitro. “Ex vivo” refers to methods conducted within or on cells or tissue in an artificial environment outside an organism with minimum alteration of natural conditions. In contrast, the term “in vivo” refers to a method that is conducted within living organisms in their normal, intact state, while an “in vitro” method is conducted using components of an organism that have been isolated from its usual biological context.

In embodiments where the methods are conducted in vitro or ex vivo, the cancer cell may be a tumor or cancer cell line. Tumor and cancer cell lines may be obtained commercially or from public sources. Examples of commercially or publically available sources from which tumor or cancer cell lines can be purchased include, but are not limited to, the American Type Culture Collection (ATCC), Manassas, Va.; Deutsche Sammlung von Mikroorganismen and Zellkulturen GmbH (DSMZ) Braunschweig, Germany; Cell Line Service (CLS), Germany; and European Collection of Cell Cultures (ECACC), Salisbury, Great Britain.

In other embodiments, the methods described herein are performed in vivo, i.e., the one or more elephant TP53-encoding nucleic acids sequences, the one or more elephant p53 proteins, or compositions thereof are administered directly to an animal in need thereof, desirably a mammal (such as those described herein), and preferably a human suffering from cancer. The methods described herein are well suited for in vivo administration to a mammal, e.g., a human, canine, etc. The one or more elephant nucleic acid sequences, proteins, or composition can be administered to a mammal (e.g., a human, canine, etc.) using standard administration techniques, including oral, intravenous, intraperitoneal, subcutaneous, pulmonary, transdermal, intramuscular, intranasal, buccal, sublingual, or suppository administration. The composition preferably is suitable for parenteral administration. The term “parenteral,” as used herein, includes intravenous, intramuscular, subcutaneous, rectal, vaginal, and intraperitoneal administration. More preferably, the composition is administered to a mammal using peripheral systemic delivery by intravenous, intraperitoneal, or subcutaneous injection. In certain embodiments, the effect of delivery to the cancer cell of the one or more elephant nucleic acid sequences, proteins, or composition described herein is therapeutic, i.e., the effect partially or completely cures a disease and/or adverse symptoms attributable to the disease (e.g., cancer). To this end, the method described herein comprises administering a “therapeutically effective amount” of the one or more elephant nucleic acid sequences, proteins, or composition described herein. A “therapeutically effective amount” refers to an amount effective, at dosages and for periods of time necessary, to achieve a desired therapeutic result. The therapeutically effective amount may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the one or more elephant nucleic acid sequences, proteins, or composition to elicit a desired response in an individual. For example, a therapeutically effective amount of an elephant TP53 nucleic acid or protein may be an amount which increases p53 protein bioactivity in a human and/or enhances the p53 signaling pathways against a cancer. Desirably, the therapeutic effect results in the death of the cancer cell.

Alternatively, the pharmacologic and/or physiologic effect may be prophylactic, i.e., the effect completely or partially prevents a disease or symptom thereof (e.g., cancer). In this respect, the method described herein comprises administering a “prophylactically effective amount” of the one or more elephant nucleic acid sequences, proteins, or composition described herein. A “prophylactically effective amount” refers to an amount effective, at dosages and for periods of time necessary, to achieve a desired prophylactic result (e.g., prevention of disease onset). Preferably, the prophylactic results in the prevention of cancer.

EXAMPLES

The following examples further illustrate the invention but, of course, should not be construed as in any way limiting its scope.

Example 1

This example describes the cancer rates in different mammal species (including elephants) to determine if body mass correlates with cancer incidence.

Necropsy data was examined from zoo animals to determine if cancer incidence increases with body size or life span. Fourteen years of necropsy data collected by the San Diego Zoo (Feng et al., PNAS, 104(42): 16633-16638 (2007)) was compiled and the tumor incidence was calculated for 36 mammalian species, spanning up to 6 orders of magnitude in size and life span (American Cancer Society; Cancer Facts & Figures (2015)). Data from the Elephant Encyclopedia (Griner et al., Pathology of Zoo Animals; Zoological Society of San Diego (1983)) was used to analyze the cause of death for captive African (Loxodonta africana) and Asian (Elephas maximus) elephants, and to estimate the age incidence and overall lifetime cancer risk. Using a previously established cancer transformation model (de Magalhaes et al., J Evol Biol; 22(8): 1770-1774 (2009)), the percentage decrease in the cellular mutation rate was calculated to account for a 100× increase in cell mass (the difference between elephants and humans) without cancer development.

TABLE 1 Observed Inferred % % # # # # # # cancer cancer Age Total Euthanized Non-cancer Exogenous Euthanized Disease Euthanized # [95% [95% Range Necropsies non-cancer disease mortality unspecified unspecified Cancer Cancer CI] CI] 0-5 125 15 77 28 1 2 0 2 1.60 2.40 [0.00, 4.24] [0.00, 5.44]  6-15 83 20 36 19 4 1 1 2 3.61 6.02 [0.00, 8.02] [0.58, 11.47] 16-25 121 35 48 25 7 2 2 2 3.31 4.96 [0.00, 6.69] [0.86, 9.05] 26-35 108 27 51 15 8 4 3 0 2.78 3.70 [0.00, 6.11] [0.00, 7.60] 36-45 94 32 27 13 12 5 0 5 5.32% 6.38 [0.47, 10.16] [1.18, 11.58] 46-55 70 14 23 7 7 17 1 1 2.86 5.71 [0.00, 7.37] [0.00, 11.59] 56+ 43 3 7 6 7 19 1 0 2.33 6.98 [0.00, 8.16] [0.00, 15.29] Lifetime 644 146 269 113 46 50 8 12 3.11 4.81 [0-56+] [1.74, 4.47] [3.14, 6.49]

The 36 mammalian species analyzed spanned from the striped grass mouse (weight of 51 g, maximum life span of 4.5 years) to the elephant (weight of 4800 kg, maximum life span of 65 years). Cancer risk did not increase with mammalian body size and maximum life span among the 36 species analyzed (e.g., for rock hyrax, 1% [95% CI, 0%-5%]; African wild dog, 8% [95% CI, 0%-16%]; and lion, 2% [95% CI, 0%-7%]) (FIG. 1 ). No significant relationship was found with any combinations of mass, life span, and basal metabolic rate and cancer incidence. Among the 644 annotated elephant deaths from the Elephant Encyclopedia database, the lifetime cancer incidence was found to be 3.11% (95% CI, 1.74%-4.47%) (Table 1). To obtain a more conservative estimate, an inferred cancer incidence was calculated for cases that lacked adequate details for the cause of death, leading to an estimated elephant cancer mortality rate of 4.81% (95% CI, 3.14%-6.49%). Based on an algebraic model of carcinogenesis (de Magalhaes et al., J Evol Biol; 22(8): 1770-1774 (2009)), a 2.17-fold decrease in mutation rate was calculated as sufficient to protect elephants from cancer development given their 100× increased cellular mass compared with humans. Overall, the cancer mortality rate for elephants was found to be less than 5% compared with a cancer mortality rate for humans of 11% to 25% (25).

The results of this example demonstrate that larger animals with longer life spans, including elephants, may develop less cancer, compared to smaller animals.

Example 2

This example describes a genomic analysis of cancer-related genes in elephants.

Genomic sequence analysis was performed on the publicly available scaffolds of the African elephant genome in the Ensembl database (release 72) and the NCBI GenBank database; specifically, cancer-related genes (including oncogenes and tumor suppressors) were examined. Sequence alignments of TP53 were explored in related species, and African and Asian elephant TP53 retrogenes were cloned and resequenced. Capillary sequencing was performed on single elephants to avoid issues of single-nucleotide polymorphisms (SNPs) between elephants. Whole genome sequencing (ILLUMINA® HISEQ 2500® Sequencing System; Illumina Inc., San Diego, CA) was performed on freshly extracted DNA from an African elephant at 40× average sequence coverage, with more than 100× coverage within areas of the TP53 gene.

A maximum likelihood phylogeny was used to cluster the sequenced TP53 retrogene clones and to confirm the number of unique genes uncovered in the African elephant genome. The phylogeny allowed for visualization of TP53 retrogene similarity to one another as well as their relationship to the ancestral TP53 sequence in the elephant and hyrax. The capillary sequenced clones from this study are shown as circles and the published sequences from GenBank are shown as squares. The African elephant (L. africana) draft genome LoxAfr3 contains 19 copies of TP53 (FIG. 2 ). Phylogenic analysis reveals at least 18 distinct clusters of processed TP53 copies. These clusters fall into 2 groups, labeled Group A and Group B. The human haploid genome contains 1 copy of TP53, while Ensembl and GenBank annotate a large number of TP53 paralogs in the African elephant genome (12 and 20 haploid copies, respectively). Elephant sequence alignments revealed that one TP53 copy with a comparable gene structure to TP53 was found in other mammalian species (ancestral copy).

The other 19 copies lacked true introns, suggesting that they originated from retrotransposition (retrogenes). Whole-genome sequencing with deep coverage confirmed one ancestral copy and 19 total retrogene copies, similar to the 20 total copies annotated in GenBank for TP53. Eleven of the 18 retrogenes from the capillary sequencing were similar, but not identical, to previous Gen-Bank annotations and local whole genome sequencing data. High variance in coverage across reference TP53 copies indicated additional TP53 elephant copies that may not yet have been successfully assembled.

There was no evidence for 8 of the published retrogene copies, possibly because of under-sampling of clones, misassembly in the published genome, or differences between individual elephants. An additional 7 cloned sequences had support from multiple clones but were not found in either database. It is also possible that TP53 copies in the genome may have been undetected by the polymerase chain reaction (PCR) primers. The Asian elephant DNA was also found to contain 15 to 20 copies of Group A and B TP53 retrogenes.

In order to establish whether elephants express TP53 retrogenes (EP53^(r)), functional molecular analysis of TP53 and its retrogenes was performed on peripheral blood mononuclear cells (PBMCs) from African and Asian elephants, and fibroblasts from an African elephant. The RNA was isolated from PBMCs and fibroblasts that were exposed to 2 Gy ionizing radiation, and reverse transcription-polymerase chain reaction (RT-PCR) was performed. The PCR primers were designed to distinguish the TP53 retrogenes from the ancestral sequence (EP53^(anc)) and splice variants. The RT-PCR products were observed at 201 bp and 185 bp on a gel (FIG. 3A), the expected sizes for the Group A and Group B EP53 retrogenes, respectively, and Sanger sequencing confirmed their identities as retrogenes. A higher resolution image is shown in FIG. 3B.

The results of this example suggest that elephants have 19 TP53 retrogenes (EP53^(r)), which can be divided into two groups (Group A and Group B), and one ancestral TP53 gene (EP53^(anc)).

Example 3

This example demonstrates whether elephant EP53 retrogenes transfected into human cell lines could be translated into proteins.

Mammalian expression vectors were cloned to produce elephant p53 retrogene (EP53^(r)) proteins fused to an epitope from the myc protein. The myc tag was used to immunoprecipitate the translated protein from cell lysates, and/or to probe for the protein on a western blot. Constructs were developed for five different EP53^(r)s: retrogene 1, retrogene 5, retrogene 7, retrogene 9, and retrogene 17. These retrogenes were selected because they represent the spectrum of different EP53 genes. All 5 EP53^(r)s were expressed as truncated proteins, compared to the full size of the EP53 protein, which runs around 53 kDa (similar to human p53).

Human embryonic kidney cells (HEK293), mouse fibroblasts (NIH 3T3), and human osteosarcoma cells (U-2OS) were transfected with one of the myc-tagged EP53^(r) plasmids (myc-EP53^(r)). The data from the HEK293 cells are shown, and are representative of the experiments performed in the other cells types. Lipid-based transfection was performed, and the cells were also transfected with empty vector as a negative control. 24 hours after transfection, the cells were placed in media containing antibiotics to selectively kill cells that did not express the gene of interest. Once selection was complete, doxycycline was added to induce gene expression, which was confirmed by western blot.

The cancer cell lines U-2OS (osteosarcoma) and HCT116 (colon cancer) were also infected with lentiviral vectors to generate stable cell lines expressing elephant EP53^(r) proteins. The plasmids used to make lentiviruses were tetracycline-inducible gene expression plasmids, in which the gene of interest is only expressed when cells are treated with doxycycline. 24 hours after viral transduction, cells were placed in media containing antibiotics to eliminate cells that did not express the gene of interest. Once selection was complete, expression of the gene of interest was confirmed by western blot.

P53 is unregulated in response to DNA damage, so to confirm that the transfected or transduced cells could express the genes of interest, the cells were treated with either MG132 (a protease inhibitor) or doxorubicin (intercalates with DNA to prevent macromolecular biosyntehsis) to induce DNA damage. For tetracycline inducible cells, the cells were treated with doxycycline for 24-48 hours prior to treatment with MG132 or doxorubicin. After the induction of DNA damage, the cells were harvested and pelleted. The cell pellets were frozen, and then lysed in cell lysis buffer containing phosphatase and protease inhibitors. The cell lysates were run on SDS-PAGE protein gels, and then transferred to PVDF membranes (western blots). The membranes were blocked, and then probed with primary antibodies to determine the p53 protein levels. The blots were probed with secondary HRP-conjugated antibodies, and the protein levels were detected using a substrate and a chemiluminometer. GAPDH was used as a loading control for each western blot. The blots were also probed for phosphorylated EP53^(r) at the serine-15 residue (phospho-EP53^(r)). DNA damage induces the phosphorylation of p53, which reduces the interaction of this protein with its negative regulator, mouse double minute 2 (MDM2) (Milczarek et al. Life Sci; 60: 1-11 (1997)).

Following treatment of the transfected cells with 10 μM MG132 or 1 μM doxorubicin, an increase in protein labeling was observed for all five EP53^(r)s in HEK293 cells, as well as an increase in the labeling for phospho-EP53^(r) (FIGS. 4A and 4B). This suggested successful transfer of the genes to the cells, and that the EP53^(r) genes could be translated into proteins. The increase in phospho-EP53^(r) confirmed that MG132 was preventing proteasomal degradation of the elephant protein. It was next determined whether the EP53^(r)s could interact with the negative regulator, MDM2. To determine if the EP53^(r)s could bind MDM2, HEK293 cells were transfected with EP53^(r9), and subjected to 6 Gy ionizing radiation to induce DNA damage. The expressed EP53^(r9) protein was then immunoprecipitated with an antibody to the myc tag, and run on a western blot. Immunoblots showed that 6 Gy ionizing radiation increased EP53^(r9) expression and phosphorylation, indicative of protein stabilization upon DNA damage, and additionally that MDM2 co-immunoprecipitated with myc-EP53^(r9), indicating that the two proteins do interact (FIG. 4C).

The results of this example demonstrate that myc-EP53^(r)s can be transfected into cells and generate protein in response to DNA damage, and interact with MDM2.

Example 4

This example describes the cellular response to DNA damage in peripheral blood lymphocytes of elephants and humans.

Experiments were performed on peripheral blood lymphocytes (PBLs) from three groups of subjects: African and Asian elephants, a representative clinical cohort of patients with Li-Fraumeni Syndrome (LFS) enrolled in the Cancer Genetics Study at the University of Utah, and age-matched human controls without a significant family history of cancer (also enrolled in the Cancer Genetics Study). Patients with LFS were selected for inclusion as a representative sample based on their TP53 mutation status, varied cancer history, and availability for blood draws. Follow-up laboratory experiments were also performed on African elephant fibroblasts, human fibroblasts, and HEK293 cells to confirm the results.

Ionizing radiation (0.5, 2, 5, 6, 10, and 20 Gy) or doxorubicin (0.005-30 μM) were used to induce DNA damage in the cultured primary PBLs, which were then evaluated for signs of apoptosis, DNA repair efficiency, and cell cycle arrest. Apoptosis was evaluated by measuring the number of cells that stained for Annexin V (AV) and propidium iodide (PI); cells were categorized as being in late apoptosis if they were AV+PI+, and in early apoptosis if they were AV+PI−. Apoptosis was also measured either using APO-TOX GLO™ (Promega, Madison, WI) or CASPASE-GLO® 3/7 Assay (Promega) and CELLTITER-GLO® (Promega). The results were normalized to cell viability either using counts from the MULTI-TOX-FLUOR™ assay (Promega) included with APO-TOX GLO™, or using CELLTITER-GLO® when caspase activity was measured. Statistically significant differences in apoptosis were calculated in GRAPHPAD PRISM®.

Following 2 Gy and 6 Gy ionizing radiation, African elephant PBLs exhibited apoptosis at significantly elevated rates, compared with human PBLs, after 18 hours (late apoptosis: 33.20% compared to 14.07%, respectively; P<0.001 (FIG. 5A); early apoptosis: 21.07% compared to 11.73%, respectively; P<0.001 (FIG. 5B)). African elephant lymphocytes also exhibited a significant increase in late (FIG. 6A) and early (FIG. 6B) apoptosis at 18 and 24 hours when exposed to 5 μM of doxorubicin.

Peripheral blood lymphocytes from individuals with LFS (n=10), healthy controls (n=10), and 1 African elephant, treated with 2 Gy of ionizing radiation revealed different levels of apoptosis (apoptosis calculated by subtracting the percentage of AV+PI+ cells treated with 2 Gy ionizing radiation, from the percentage of AV+PI+ cells cultured without treatment). Cells of patients with LFS underwent significantly less apoptosis compared with healthy human PBLs (2.71% relative to 7.17%; P<0.001) and elephant PBLs (14.64%; P<0.001) (FIG. 7 ).

Similar to lymphocytes, a higher rate of apoptosis (as a metric of increased caspase 3/7 cleavage) was also observed in elephant fibroblasts (FIG. 8 ) subjected to DNA damage by 10 μM and 30 μM doxorubicin (elephant: 9.1-fold increase; human: 2.24-fold increase; P<0.001). The elephant fibroblasts cells additionally showed reduced viability consistent with cell cycle arrest after 0.5 Gy of ionizing radiation (elephant: 80.81% compared to human: 95.87%; P=0.01).

P53 plays a critical role in p21 and MDM2 protein induction following DNA damage (Macleod et al, Genes Dev; 9(8): 935-944 (1995); Yoon et al. PNAS; 99(24): 15632-15637 (2002)), so p21 expression was evaluated on immunoblots to validate that the DNA damage response in elephant cells to radiation was dependent on P53. Both elephant and human PBLs showed an increase in p53 and p21 protein expression following ionizing radiation exposure (FIG. 9 ). More p21 protein expression was observed at 5 hours in elephant PBLs treated with 0.5 Gy of ionizing radiation compared with human PBLs (20.1-fold increase relative to 3.5-fold increase; P=0.004). Elephant fibroblasts also showed increased p21 protein expression following 2 Gy of ionizing radiation at 5 hours (1.9-fold increase) compared with no increase in human fibroblasts.

As a post hoc analysis, the same experiments were repeated in PBLs from multiple Asian elephants (n=6) of different ages (2, 12, 17, 38, 57, and 69 years old). Asian elephant lymphocytes also demonstrated an increased rate of apoptosis (50.63% relative to human cells 23.67%; P<0.001) when exposed to 2 Gy of ionizing radiation (FIG. 10A) and an increase in p21 expression (FIG. 10B). Additionally, the apoptotic response in PBLs decreased with the age of Asian elephants when tested with both a linear regression and a Jonckheere-Terpstra test, which allows for nonlinear relationships (FIG. 10C) (2-year-old elephant with 2 Gy radiation at 18 hours, 52.53% [95% CI, 35.86%-69.2%] and 69-year-old elephant, 40.03% [95% CI, 30.64%-49.43%]; P=0.002 by linear regression; P<0.001 by Jonckheere-Terpstra test).

HEK293 cells express adenovirus proteins that naturally inhibit the function of p53; however the mouse fibroblast cell line, NIH3T3, expresses a functional TP53 gene. Therefore additional studies were conducted in NIH3T3 cells to test the effect on cell survival of EP53^(r5) and EP53^(r9) expression in cells that also express functional wild type TP53. NIH3T3 cells were transfected with EP53^(r5) or EP53^(r9) and then treated with doxorubicin to induce DNA damage. As shown in FIG. 11 , a significant increase in caspase activity of the NIH 3T3 cells transfected with EP53^(r5) (FIG. 11A) and EP53^(r9) (FIG. 11B) was observed relative to control cells, suggesting that EP53^(r5) and EP53^(r9) expression increases apoptosis in cells that already express functional TP53.

TABLE 2 % of viable cells with the indicated # of pH2AX foci 0-5 foci 6-10 foci 11-15 foci 16-20+ foci Treatment Human Elephant Human Elephant Human Elephant Human Elephant NT 1 h 97.3 98.7 2.7 1.3 0.0 0.0 0.0 0.0 NT 5 h 97.7 98.0 2.3 1.3 0.0 0.7 0.0 0.0 NT 24 h 99.7 99.7 0.3 0.3 0.0 0.0 0.0 0.0 2GY 1 h 23.0 26.3 25.3 33.7 19.0 17.0 32.7 23.0 2GY 5 h 46.7 51.0 32.7 39.0 14.3 9.0 6.3 1.0 2GY 24 h 94.3 92.3 5.3 7.3 0.3 0.0 0.0 0.0

The efficiency of DNA repair was next evaluated by determining the number of phospho-histone H2AX (pH2AX) labeled foci, an indicator of double-stranded breaks in the DNA. The cells were cultured for 1, 5, 10, 18, 24, and 72 hours after the induction of DNA damage by 2 Gy ionizing radiation, and then evaluated. Lymphocytes undergo p53-dependent apoptosis in response to DNA damage (Heinrichs et al. Oncogene; 22(4): 555-571 (2003); Lowe et al. Cell; 74(6): 957-967 (1993)), while fibroblasts undergo both p53-dependent apoptosis and cell cycle arrest (Antoccia et al. J Radial Res; 50(5): 457-468 (2009); Kastan et al. Cell; 71(4): 587-597 (1992); Attardi et al. Oncogene; 23(4): 973-980 (2004)); both elephant cell types were tested accordingly.

Ionizing radiation did not cause a significant difference in the percentage of cells with labeled pH2AX foci in human and elephant PBLs, indicating that the increased apoptosis in elephants cannot be attributed to more DNA damage (Table 2). Cells were binned by the number of pH2AX foci (0-5, 6-10, 11-15, 16-20+), and demonstrated no significant difference in the rate of DNA damage repair between humans and elephants.

TABLE 3 Log 2 Increase Gene Name Compared to NT Adjusted P Value MDM2 2.62 1.24E−166 CCNG1 2.13 2.68E−140 TP53INP1 2.69 1.31E−134 DIS3 1.53 1.70E−88 PLXNB2 3.51 3.54E−86 BAX 1.83 2.77E−78 PHLDA3 5.79 3.85E−72 DNA2 2.19 2.15E−68 RPS27L 2.04 3.83E−60 ZNF608 1.73 1.07E−58 ZMAT3 2.83 2.24E−54 CHST14 2.63 1.04E−51 SDK2 3.31 8.14E−46 FAT1 2.40 2.27E−45 TNS1 3.93 4.51E−37 IZUMO4 3.05 1.13E−30 POLH 1.73 1.78E−30 PVRL4 2.92 3.59E−29 PLXNA2 2.78 3.04E−28 SNAI3 2.94 5.57E−28

To identify changes in gene expression in elephant cells in response to DNA damage, elephant peripheral blood lymphocytes were treated with 2 Gy ionizing radiation. Irradiated and untreated cells were cultured at 37° C. for 5 hours. RNA was extracted from the cells and treated with DNase to remove genomic DNA. RNA-sequencing was performed, and the top 20 most upregulated genes in elephant cells after exposure to radiation were compiled. In Table 3, genes highlighted in gray are known targets or regulators of p53 in human cells. These results suggest that DNA damage induces p53-dependent signaling pathways in elephant cells, similar to the p53-signaling pathways induced by DNA damage in human cells.

The results of this example demonstrate that elephant cells execute higher levels of apoptosis in response to DNA damage, and that when EP53 proteins are transduced into human cells, these cells are able to execute higher levels of apoptosis in response to DNA damage.

Example 5

This example evaluates whether EP53 expression could increase apoptosis of the human cancer line, U-2OS (osteosarcoma) transfected with various EP53 genes.

U-2OS cells were transfected with EP53^(r5) or EP53 ancestral (EP53^(anc)), and then treated with doxycycline to induce EP53^(r) expression. The cells were then treated with doxorubicin to damage the DNA. As shown in FIG. 12A, a significant increase in caspase activity was observed in the EP53^(r5)-transduced cell line compared to control cells with an empty vector, suggesting that EP53^(r5) expression increases apoptosis of cancer cells that also express functional TP53.

U-2OS cells were also transduced with EP53^(anc). These cells were then induced to express EP53^(anc), and treated with doxorubicin to trigger DNA damage. As shown in FIG. 12B, cells induced to express EP53^(anc) had a 20-fold increase in caspase activity, compared to cells transduced with an empty vector. These cells exhibited more phosphor-EP53^(anc), as was an increase in the p53 target genes, p21 and MDM2 (FIG. 12C). Cells that expressed EP53^(anc) also expressed less endogenous human p53. Even in the absence of doxorubicin treatment, U-2OS cells expressing EP53^(anc) underwent significant apoptosis compared to cells that were transduced with empty vector.

Additional experiments were conducted in which U-2OS cells were transfected with EP53^(r9) tagged with GFP (GFP-EP53^(r9)). After 24, 48, or 72 hours post-transfection, the cells were harvested and the whole cell lysates were processed for western blotting. The blots were probed for phospho-EP53^(r9), as well as endogenous human phosphor-p53. It was found that in addition to increased expression of EP53R9, the U-2OS cells exhibited restoration of the wild type p53 response, which induced apoptosis of these cells (FIG. 13 ).

U-2OS cells were also transfected with EP53^(anc) and human TP53, and the cell viability after induction with doxycycline was observed after 72 hours. It was found that in cells transfected with elephant p53, cell viability dropped to 35.6% (SEM 1.85), whereas cells transduced with human p53 only dropped to 46.1% (SEM 1.12) cell viability, suggesting that elephant p53 is able to kill more human cancer cells than human p53 alone. The U-2OS cells transfected with EP53^(anc) also saw an increase in caspase activity (14.22%, SEM 0.23) relative to cells transfected with human p53 (10.89%, SEM 0.12), consistent with an increase in apoptotic activity following induction of elephant p53 proteins.

To examine the effect of EP53^(r9) expression on cellular senescence of human colon cancer cells, HCT116 cancer cells were transduced with a tetracycline-inducible vector encoding EP53^(r9). Protein expression was then induced with doxycycline, and cells were then treated with doxorubicin to damage the DNA. HCT116-EP53^(r9) cells exhibited significantly more caspase activity compared to control cells (FIG. 14A). Western blots were performed to confirm expression of EP53^(r9) in these cells (FIG. 14B). It was found that cells treated with increasing concentrations of doxycycline expressed more endogenous human phosphorylated-p53 (Ser15) compared to cells that did not express EP53^(r9). The cells were transduced with flag-tagged EP53^(r9), and an antibody to flag was used to verify expression of EP53^(r9). Cells were treated with 5-FU to activate the p53 pathway. These results suggest that EP53^(r9) increased apoptosis by increasing the amount of activated endogenous p53 in these cells.

The results of this example demonstrate that induction of EP53 in cancer cell lines causes a significant increase in apoptosis.

All references, including publications, patent applications, and patents, cited herein are hereby incorporated by reference to the same extent as if each reference were individually and specifically indicated to be incorporated by reference and were set forth in its entirety herein.

The use of the terms “a” and “an” and “the” and “at least one” and similar referents in the context of describing the invention (especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. The use of the term “at least one” followed by a list of one or more items (for example, “at least one of A and B”) is to be construed to mean one item selected from the listed items (A or B) or any combination of two or more of the listed items (A and B), unless otherwise indicated herein or clearly contradicted by context. The terms “comprising,” “having,” “including,” and “containing” are to be construed as open-ended terms (i.e., meaning “including, but not limited to,”) unless otherwise noted. Recitation of ranges of values herein are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., “such as”) provided herein, is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention unless otherwise claimed. No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the invention.

Preferred embodiments of this invention are described herein, including the best mode known to the inventors for carrying out the invention. Variations of those preferred embodiments may become apparent to those of ordinary skill in the art upon reading the foregoing description. The inventors expect skilled artisans to employ such variations as appropriate, and the inventors intend for the invention to be practiced otherwise than as specifically described herein. Accordingly, this invention includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination of the above-described elements in all possible variations thereof is encompassed by the invention unless otherwise indicated herein or otherwise clearly contradicted by context. 

1. A method of inhibiting cancer, which comprises contacting a cancer cell with (a) one or more nucleic acid sequences each encoding an elephant p53 protein, or (b) one or more elephant p53 proteins, whereby the cancer is inhibited.
 2. The method of claim 1, which comprises contacting the cancer cell with one or more nucleic acid sequences each encoding an elephant p53 protein.
 3. The method of claim 2, wherein a nucleic acid sequence encoding an elephant p53 protein is a retrogene.
 4. The method of claim 2, wherein a nucleic acid sequence encoding an elephant p53 protein is an ancestral gene.
 5. The method of claim 2, which comprises contacting the cancer cell with multiple nucleic acid sequences, each encoding an elephant p53 protein.
 6. The method of claim 5, wherein the multiple nucleic acid sequences comprise multiple different retrogenes.
 7. The method of claim 6, wherein at least one of the multiple nucleic acid sequences comprises an ancestral gene.
 8. The method of any of claims 1-7, wherein the one or more nucleic acid sequences comprise RNA or DNA.
 9. The method of claim 3 or claim 6, wherein the retrogene comprises a nucleic acid sequence of SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 22, SEQ ID NO: 24, SEQ ID NO: 26, SEQ ID NO: 28, SEQ ID NO: 30, SEQ ID NO: 32, SEQ ID NO: 34, SEQ ID NO: 36, SEQ ID NO: 38, SEQ ID NO: 40, SEQ ID NO: 42, SEQ ID NO: 44, SEQ ID NO: 46, SEQ ID NO: 48, SEQ ID NO: 50, SEQ ID NO: 52, SEQ ID NO: 54, SEQ ID NO: 56, SEQ ID NO: 58, SEQ ID NO: 60, SEQ ID NO: 62, SEQ ID NO: 64, SEQ ID NO: 66, SEQ ID NO: 68, SEQ ID NO: 70, SEQ ID NO: 72, SEQ ID NO: 74, or SEQ ID NO:
 76. 10. The method of claim 4 or claim 7, wherein the ancestral gene comprises a nucleic acid sequence of SEQ ID NO:
 2. 11. The method of claim 1, which comprises contacting the cancer cells with one or more elephant p53 proteins.
 12. The method of claim 11, which comprises contacting the cancer cell with one elephant p53 protein.
 13. The method of claim 12, wherein the elephant p53 protein is encoded by a retrogene.
 14. The method of claim 13, wherein the elephant p53 protein is encoded by an ancestral gene.
 15. The method of claim 11, which comprises contacting the cancer cell with multiple different elephant p53 proteins.
 16. The method of claim 15, wherein the multiple different elephant p53 proteins are encoded by multiple different retrogenes.
 17. The method of claim 16, wherein at least one of the multiple different elephant p53 proteins is an ancestral p53 protein.
 18. The method of claim 13 or claim 16, wherein the P53 protein comprises an amino acid sequence of SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 21, SEQ ID NO: 23, SEQ ID NO: 25, SEQ ID NO: 27, SEQ ID NO: 29, SEQ ID NO: 31, SEQ ID NO: 33, SEQ ID NO: 35, SEQ ID NO: 37, SEQ ID NO: 39, SEQ ID NO: 41, SEQ ID NO: 43, SEQ ID NO: 45, SEQ ID NO: 47, SEQ ID NO: 49, SEQ ID NO: 51, SEQ ID NO: 53, SEQ ID NO: 55, SEQ ID NO: 57, SEQ ID NO: 59, SEQ ID NO: 61, SEQ ID NO: 63, SEQ ID NO: 65, SEQ ID NO: 67, SEQ ID NO: 69, SEQ ID NO: 71, SEQ ID NO: 73, SEQ ID NO: 75, and SEQ ID NO:
 77. 19. The method of claim 14 or claim 17, wherein the p53 protein comprises an amino acid sequence of SEQ ID NO:
 3. 20. The method of any one of claims 1-19, wherein the one or more nucleic acid sequences or the one or more elephant p53 proteins are in the form of a composition, which composition comprises a pharmaceutically-acceptable carrier.
 21. The method of claim 20, wherein the composition comprises a liposome.
 22. The method of claim 21, wherein the one or more nucleic acid sequences or one or more p53 proteins are encapsulated within the liposome.
 23. The method of claim 20, wherein the composition comprises a nanoparticle.
 24. The method of claim 23, wherein the nanoparticle comprises one or more fillers selected from the group consisting of an organic substance, an inorganic substance, a lipid, a polymer, a metal, and a carbon nanostructure.
 25. The method of claim 23 or 24, wherein the nanoparticle comprises the elephant p53 protein or elephant TP53 nucleic acid encapsulated within a liposome.
 26. The method of any one of claims 23-25, wherein the nanoparticle comprises an external surface decorated with a moiety for reducing an interaction with the reticuloendothelial system.
 27. The method of claim 26, wherein the moiety comprises polyethylene glycol.
 28. The method of claim 26, wherein the moiety comprises a targeting moiety.
 29. The method of claim 28, wherein the targeting moiety increases the affinity of the nanoparticle for the cancer cell.
 30. The method of any one of claims 20-29, wherein the composition further comprises one or more additives selected from the group consisting of a small molecule chemotherapeutic, a monoclonal antibody, and an imaging agent.
 31. The method of claim 30, wherein the imaging agent comprises a contrast agent, a sugar, an iron complex, or gadolinium (Gd).
 32. The method of any one of claims 1-31, wherein the cancer cell is in vitro or in vivo.
 33. The method of any one of claims 1-32, wherein the cancer cell is derived from a mammal.
 34. The method of claim 33, wherein the mammal is a human.
 35. A composition comprising a pharmaceutically acceptable carrier and (a) one or more nucleic acid sequences each encoding an elephant p53 protein or (b) one or more elephant p53 proteins.
 36. The composition of claim 34, which comprises one or more nucleic acid sequences each encoding an elephant p53 protein.
 37. The composition of claim 34 or 35, wherein the one or more nucleic acid sequences comprise RNA or DNA.
 38. The composition of claim 34, which comprises one or more elephant p53 proteins.
 39. The composition of claim 34, which comprises a liposome.
 40. The composition of claim 38, wherein the one or more nucleic acid sequences or one or more P53 proteins are encapsulated within the liposome.
 41. The composition of claim 34, which comprises a nanoparticle.
 42. The composition of claim 40, wherein the nanoparticle comprises one or more fillers selected from the group consisting of an organic substance, an inorganic substance, a lipid, a polymer, a metal, and a carbon nanostructure.
 43. The composition of claim 40 or claim 41, wherein the one or more nucleic acid sequences or one or more p53 proteins are encapsulated within a liposome.
 44. The composition of any one of claims 40-42, wherein the nanoparticle comprises an external surface decorated with a moiety for reducing an interaction with the reticuloendothelial system.
 45. The composition of claim 43, wherein the moiety comprises polyethylene glycol.
 46. The composition of claim 43, wherein the moiety comprises a targeting moiety.
 47. The composition of claim 45, wherein the targeting moiety increases the affinity of the nanoparticle for the cancer cell.
 48. The composition of any one of claims 34-46, which further comprises one or more additives selected from the group consisting of a small molecule chemotherapeutic, a monoclonal antibody, and an imaging agent.
 49. The composition of claim 47, wherein the imaging agent comprises a contrast agent, a sugar, an iron complex, or gadolinium (Gd). 